We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+13.68%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$568M
AUM Growth
–
Cap. Flow
+$533M
Cap. Flow %
93.89%
Top 10 Hldgs %
47.49%
Holding
49
New
48
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$36.3M
2
ALGN icon
Align Technology
ALGN
+$36.1M
3
HCA icon
HCA Healthcare
HCA
+$28.4M
4
CAH icon
Cardinal Health
CAH
+$26.7M
5
ARRY
Array Biopharma Inc
ARRY
+$25.7M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 81.21%
2 Miscellaneous 14.96%
3 Communication Services 1.99%
4 Consumer Staples 1.28%
5 Industrials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDA icon
26
Sonida Senior Living
SNDA
$1.8B
$10.1M 1.78%
+28,187
New +$10.7M
TRNX
27
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$9.61M 1.69%
+549,100
New +$9.43M
WAT icon
28
Waters Corp
WAT
$40.7B
$7.97M 1.4%
+79,664
New +$7.63M
NBIX icon
29
Neurocrine Biosciences
NBIX
$15.7B
$7.77M 1.37%
+580,500
New +$7.13M
WOOF
30
DELISTED
VCA Inc.
WOOF
$7.25M 1.28%
+278,000
New +$6.74M
CYBX
31
DELISTED
CYBERONICS INC
CYBX
$7.23M 1.27%
+139,100
New +$6.59M
ABMD
32
DELISTED
Abiomed Inc
ABMD
$7.03M 1.24%
+326,189
New +$6.56M
OREX
33
DELISTED
Orexigen Therapeutics, Inc.
OREX
$6.96M 1.23%
+119,044
New +$7.32M
PACB icon
34
Pacific Biosciences
PACB
$435M
$6.2M 1.09%
+2,450,580
New +$6.1M
FOLD
35
DELISTED
Amicus Therapeutics
FOLD
$5.53M 0.97%
+2,373,687
New +$7.3M
BSTC
36
DELISTED
BioSpecifics Technologies Corp.
BSTC
$4.87M 0.86%
+312,152
New +$5.02M
CCXI
37
DELISTED
ChemoCentryx, Inc.
CCXI
$3.61M 0.64%
+255,100
New +$3.31M
ALXN
38
DELISTED
Alexion Pharmaceuticals
ALXN
$3.57M 0.63%
+38,700
New +$3.73M
BGMS
39
Bio Green Med Solution Inc
BGMS
$5.7M
$3.18M 0.56%
+1
New +$3.41M
KYTH
40
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$2.98M 0.52%
+110,118
New +$2.52M
PPH icon
41
VanEck Pharmaceutical ETF
PPH
$993M
$296K 0.05%
+6,500
New +$301K
IBB icon
42
iShares Biotechnology ETF
IBB
$10.5B
$261K 0.05%
+4,500
New +$260K
ABT icon
43
Abbott
ABT
$195B
$251K 0.04%
+7,200
New +$264K
SLXP
44
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$218K 0.04%
+3,300
New +$189K
UNH icon
45
UnitedHealth
UNH
$353B
$210K 0.04%
+3,200
New +$199K
IDIX
46
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$109K 0.02%
+30,200
New +$124K
XNPT
47
DELISTED
XENOPORT, INC.
XNPT
$62K 0.01%
+12,500
New +$75.8K
DVAX
48
DELISTED
Dynavax Technologies
DVAX
$55K 0.01%
+5,000
New +$105K
1
2

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Redmile Group, which disclosed 49 positions worth $568M. Its ten largest holdings account for 47% of the portfolio.

Its largest position is ONYX PHARMACEUTICALS INC: 393,981 shares worth $34.2M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, followed by Miscellaneous and Communication Services.

  • Redmile Group's largest Q2 2013 buy was ONYX PHARMACEUTICALS INC: 393,981 shares worth $34.2M.
  • Redmile Group's ten largest holdings make up 47% of its $568M portfolio in Q2 2013.
  • Redmile Group disclosed 49 positions in Q2 2013, its first 13F filing on record.

Based on Redmile Group's 13F filing for Q2 2013, filed 14 Aug 2013.